STW.nl

U bent hier

Novel Antibacterial Compounds and Therapies Antagonizing Resistance (NACTAR)

The Dutch Ministry of Ministry of Health, Welfare and Sport and NWO Domain AES have jointly commissioned an ambitious research programme on the development of new antibiotics and alternatives to antibiotics. As a result, we present a research programme focussing on 'Novel Antibacterial Compounds and Therapies Antagonizing Resistance' (NACTAR). The main goal of the programme is to facilitate research and development of new antimicrobial molecules and alternatives to antibiotics, which should become available for the healthcare system for a fair and affordable price.

Antimicrobial resistance (AMR) is one of the major threats to human health in the 21st century, with some bacterial pathogens acquiring resistance to all clinically available antibiotics. Worldwide, infections caused by multi-drug resistant (MDR) bacteria are now a major cause of morbidity and mortality, and have markedly increased healthcare costs. Consequently, the aim of this program is to discover, develop and exploit new resources for antibiotics and alternatives to antibiotics and to provide a trajectory for their clinical development. The NACTAR program connects to the National Antibiotic Development Platform (NADP), which was established by NCOH, CARES, CeSAM and Immuno Valley with support of the Dutch Ministry of Health, Welfare and Sport (VWS) with the aim of supporting the development of drugs to counter AMR.

The aim of the NACTAR program is to deliver new bioactive compounds and alternatives to antibiotics aimed at curing human infectious diseases caused by MDR bacteria. This includes the use of microbial hosts and methodologies to synthesize new bioactive compounds and semi-synthetic variants, characterization of their antimicrobial activity and their efficacy in infectious disease animal models. We foresee many potential patent applications, and opportunities for small-to-medium enterprises to interact with academia.

Documents
You will be able to find the documents related to the Call for proposals through the following links:

Call for proposals
Form Application - Pre Proposal
Form Application - Full Proposal
Form Financial Planning
Form Data Management
Form Declaration Main Applicant
TTW General conditions (Dutch)
TTW General conditions (English)

Begindatum 
2018
Einddatum 
2022
Contactpersoon  
Bekijk alle projecten van dit programma

The lugdunomycins: a new class of polyketide antibiotics with unique chemical scaffold

Antibiotics have been the largest revolution in modern medicine, and have eradicated devastating infectious diseases such as the plague and pestile...

Project nummer: 
16439
Deelnemende kennisinstellingen: 
Universiteit Leiden
Begindatum:
01-03-2018
, einddatum:
28-02-2022

MDR-Phage - Small molecules that promote bacterial killing in phagocytes

The MDR-Phage project aims to evaluate the effects of a novel class of molecules for the treatment of multi-drug resistant (MDR) bacteria. Prelimin...

Project nummer: 
16447
Deelnemende kennisinstellingen: 
Universiteit Twente
Begindatum:
01-02-2018
, einddatum:
31-01-2021

Bringing mycobacterial secretion inhibitors to maturation

The world is facing a steady rise in the number of tuberculosis (TB) cases with multi drug-resistant TB (MDR-TB) and extensively drug-resistant TB ...

Project nummer: 
16445
Deelnemende kennisinstellingen: 
VU Medisch Centrum Amsterdam
Begindatum:
01-01-2018
, einddatum:
01-01-2022

Chemical genetics to target intracellular drug-resistant bacteria

Virulent multi, extensively, and totally drug-resistant (MDR/XDR/TDR) bacteria are rapidly emerging. We here propose to use host-targeted treatment...

Project nummer: 
16444
Deelnemende kennisinstellingen: 
Leids Universitair Medisch Centrum
Begindatum:
01-06-2018
, einddatum:
01-06-2022

Synergistic action of designed peptides and established Gram-positive antibiotics to fight Gram-negative ESKAPE organisms

The aim of this project is to identify and develop highly efficient synergistic combinations of designed synthetic L- and D-peptides combined with ...

Project nummer: 
16433
Deelnemende kennisinstellingen: 
Rijksuniversiteit Groningen
Begindatum:
01-01-2018
, einddatum:
01-01-2022

Boosting host immunity against Klebsiella pneumoniae via therapeutic antibodies

Infections become progressively difficult to treat because of the increasing resistance of bacteria against antibiotics. Therefore, new innovative ...

Project nummer: 
16442
Deelnemende kennisinstellingen: 
Universitair Medisch Centrum Utrecht
Begindatum:
01-04-2018
, einddatum:
01-04-2022

Next stage development of the novel synthetic antimicrobial peptide SAAP-148 (NESDAP)

The emergence of antimicrobial resistance (AMR) worldwide raises fears of untreatable infections. It has been estimated that 10 million people will...

Project nummer: 
16434
Deelnemende kennisinstellingen: 
Leids Universitair Medisch Centrum
Begindatum:
01-01-2018
, einddatum:
01-01-2022

In Pursuit of Next-Generation Lipopeptide Antibiotics

The discovery of antibiotics has revolutionized medicine, extending human life span. However, the rapid development of antimicrobial resistance and...

Project nummer: 
16440
Deelnemende kennisinstellingen: 
Wageningen Universiteit en Researchcentrum
Begindatum:
01-04-2018
, einddatum:
31-03-2023
Subscribe to RSS - Novel Antibacterial Compounds and Therapies Antagonizing Resistance (NACTAR)